This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept MT
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study MT
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder CI
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug MT
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults CI
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating MT
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-19-2024 02:00 PM
Transcript : Neurocrine Biosciences, Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 12:00 PM
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing MT
Transcript : Neurocrine Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating MT
Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM
Transcript : Neurocrine Biosciences, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing MT
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment CI
Neurocrine Biosciences Insider Sold Shares Worth $1,987,047, According to a Recent SEC Filing MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating MT
Neurocrine Biosciences Insider Sold Shares Worth $376,700, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $313,530, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $290,968, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $359,041, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $737,271, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $270,284, According to a Recent SEC Filing MT
Chart Neurocrine Biosciences, Inc.
More charts
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.7 USD
Average target price
152.5 USD
Spread / Average Target
+13.23%
Consensus
  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. News Neurocrine Biosciences, Inc.
  5. Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing